AGM/EGMApr 27, 2026, 08:03 AM
NVAX 2025 Revenue $1.1B; Proposes 10.4M Share Equity Plan Increase
AI Summary
Novavax, Inc. (NVAX) reported $1.1 billion in total revenue for 2025, alongside a 42% reduction in Non-GAAP Combined R&D and SG&A expenses compared to 2024. The company ended 2025 with an $857 million cash position and a 40% reduction in total liabilities. For its 2026 Annual Meeting, Novavax proposes to increase shares available under its 2015 Stock Incentive Plan by 9.4 million and its 2013 Employee Stock Purchase Plan by 1 million shares, totaling 10.4 million new shares. The company also highlighted progress on its corporate strategy, including milestones with Sanofi and advancing its R&D pipeline.
Key Highlights
- Proposes to increase 2015 Stock Incentive Plan shares by 9,400,000.
- Proposes to increase 2013 Employee Stock Purchase Plan shares by 1,000,000.
- Total revenue in 2025 was $1.1 billion.
- Non-GAAP Combined R&D and SG&A expenses reduced by 42% in 2025 vs 2024.
- Cash position as of December 31, 2025, was $857 million.
- Total liabilities reduced by 40% compared to year-end 2024.
- Annual Meeting of Stockholders to be held virtually on June 18, 2026.
- Board recommends FOR election of three Class I directors.